StockNews.com started coverage on shares of Cytosorbents (NASDAQ:CTSO - Free Report) in a research report report published on Monday. The brokerage issued a hold rating on the medical research company's stock.
Several other research analysts have also commented on the company. D. Boral Capital restated a "buy" rating and set a $10.00 price target on shares of Cytosorbents in a research report on Friday, January 3rd. HC Wainwright reaffirmed a "neutral" rating and issued a $1.00 target price on shares of Cytosorbents in a research report on Monday, November 11th. Two research analysts have rated the stock with a hold rating, two have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, Cytosorbents currently has a consensus rating of "Moderate Buy" and an average price target of $4.67.
View Our Latest Stock Analysis on Cytosorbents
Cytosorbents Stock Performance
Shares of CTSO stock opened at $0.94 on Monday. The company has a debt-to-equity ratio of 1.06, a quick ratio of 1.58 and a current ratio of 1.97. The firm has a market cap of $51.27 million, a P/E ratio of -2.60 and a beta of 0.58. The firm's 50 day moving average price is $0.92 and its 200-day moving average price is $1.03. Cytosorbents has a one year low of $0.70 and a one year high of $1.59.
Institutional Trading of Cytosorbents
A number of institutional investors have recently bought and sold shares of CTSO. Atomi Financial Group Inc. purchased a new stake in Cytosorbents during the third quarter worth approximately $51,000. Geode Capital Management LLC lifted its position in shares of Cytosorbents by 7.5% during the 3rd quarter. Geode Capital Management LLC now owns 467,058 shares of the medical research company's stock worth $701,000 after buying an additional 32,415 shares during the last quarter. Finally, Sargent Investment Group LLC boosted its holdings in shares of Cytosorbents by 4.9% in the 2nd quarter. Sargent Investment Group LLC now owns 1,433,500 shares of the medical research company's stock valued at $1,008,000 after buying an additional 67,181 shares in the last quarter. 32.87% of the stock is owned by hedge funds and other institutional investors.
About Cytosorbents
(
Get Free Report)
Cytosorbents Corporation engages in the research, development, and commercialization of medical devices with its blood purification technology platform incorporating a proprietary adsorbent and porous polymer technology in the United States, Germany, and internationally. Its flagship product is CytoSorb, an extracorporeal cytokine adsorber for adjunctive therapy in the treatment of sepsis, adjunctive therapy in other critical care applications, prevention, and treatment of perioperative complications, and maintaining or enhancing the quality of solid organs harvested from donors for organ transplant; and offers VetResQ, a device for adjunctive therapy in the treatment of sepsis, pancreatitis, and other critical illnesses in animals.
Further Reading
Before you consider Cytosorbents, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cytosorbents wasn't on the list.
While Cytosorbents currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
